AMH Equity’s BioCryst Pharmaceuticals BCRX Stock Holding History

AMH Equity’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-80,000	Closed	-$602K	–	56
2024 Q4	$602K	Sell	80,000 -20,000	-20%	-$152K	0.59%	37
2024 Q3	$760K	Buy	+100,000	New	+$760K	0.96%	29

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AMH Equity's BCRX Position: Q1 2025 in Review

AMH Equity sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2025, closing a stake of 80,000 shares — an estimated $602K sold.

AMH Equity first reported a position in BCRX in Q3 2024 and held it in 2 quarters. The position peaked at $760K in Q3 2024. 274 funds tracked by Wall St. Rank hold BCRX as of Q1 2025.

AMH Equity reported no remaining BioCryst Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
AMH Equity sold 80,000 BioCryst Pharmaceuticals shares in Q1 2025, an estimated $602K.
AMH Equity first reported a position in BioCryst Pharmaceuticals in Q3 2024 and held it in 2 quarters.
AMH Equity's BioCryst Pharmaceuticals position peaked at $760K in Q3 2024.
274 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2025.

Based on AMH Equity's 13F filing for Q1 2025, filed 5 May 2025.